CIBA Vision to Market Implants That May
Reverse Presbyopia and Treat Glaucoma
CIBA Vision has acquired from Dallas-based Presby Corp
the rights to a surgical technique that has shown promising results in initial
clinical studies in the treatment of presbyopia, ocular hypertension and primary
open angle glaucoma.
The license agreement includes the worldwide rights
to market and sell Presby Corp¡¯s scleral expansion implants, as well as a
specialized automated incision device and blades. These products are used in a
surgical technique that has shown promising results in initial clinical studies
in the treatment of presbyopia. CIBA Vision will assume responsibility for
manufacturing the products.
The implants consist of four separate
segments made from polymethylmethacrylate (PMMA) and are implanted within the
sclera. The implants re-establish the anterior segment spacing as it is found in
a non-presbyopic eye. This minimally invasive procedure can be completed by
trained physicians on an outpatient basis using topical and/or local anesthesia.
Patients have reported improved near vision almost immediately after the
In addition to the procedure¡¯s effect on presbyopia, a study
shows promising early results that the implants can be successfully used in the
treatment of ocular hypertension and primary open angle glaucoma. For glaucoma,
the study indicates the implants work by increasing the aqueous humor
CIBA Vision expects to begin marketing and distributing the
products later this year in Europe and Canada. Presby Corp has completed Phase I
FDA trials and has received clearance to proceed with the clinical studies
required for U.S. market approval.
Refractive Surgery Trends
Results are in from the 2001 survey of the 980 U.S. members of the
International Society of Refractive Surgery. Key findings include:
LASIK remains the dominant refractive surgery for refractive
errors from -12.00 to +3.00 D
excimer laser and the Hansatome microkeratome are the most frequently used
instruments for LASIK.
SOURCE: J Refract Surg 2002;18:185-188.
The Incidence of Ocular Toxicity of
Preservatives with Glaucoma Medications
Patients who use preserved glaucoma medications are much more likely
to experience discomfort upon instillation, burning-stinging, foreign body
sensation, dry eye sensation, tearing and eyelid itching than those who use
preservative-free eyedrops, according to a survey of more than 4,100 patients.
Moreover, most of the adverse reactions induced by preserved glaucoma medication
are reversible after removing preservatives. The prevalence of signs and
symptoms was dose dependent, increasing with the number of preserved drops.
British Journal of Ophthalmology 2002;86:418-423.
Outcomes Faster, More Stable in Myopia
Patients Undergoing LASIK
Either spherical or astigmatic LASIK surgery provides
faster and more stable outcomes in myopia patients than spherical or astigmatic
photorefractive keratectomy (PRK), although all of the four procedures may yield
excellent outcomes, according to a new study.
Researchers analyzed the
visual acuity in 619 eyes of 388 consecutive patients who had refractive surgery
during a two-year period. The patients were divided in to two groups: those who
had mild-to-moderate myopia and those who had high myopia (spherical equivalent
of -6.12 D or more).
In those with mild-to-moderate myopia, the
researchers found comparable results between either a flap-based procedure or a
PRK procedure. However, the flap-based procedure yielded better results than PRK
in patients with high myopia. Corrections for astigmatism did not increase the
risk of poor visual outcome and were highly effective at reducing cylinder in
most patients, the researchers reported.
SOURCE: Van Gelder RN et al. J Cataract Refract
Increased Mortality in Women with
In diabetics, cataract is associated with higher risk of
death. In non-diabetics the data are conflicting, but some indicate an
association between one type of cataract (nuclear) and increased mortality. For
the first time, a study has shown that, among the elderly (age 65 and older)
non-diabetic population, cataract is associated with higher mortality in women
but not in men.
This sex effect suggests that women may be exposed to
risk factors that increase both the risk of cataract and mortality, and that men
may have little or no exposure to these "sex specific" factors. Possible risk
factors that warrant further investigation may be those associated with some
pregnancy and childbearing experience, the authors suggest.
mortality in women with cataract was consistent for cardiovascular, respiratory
and other non-cancer causes of death. There was no association between cataract
and mortality from cancer.
SOURCE: British Journal of Ophthalmology
- THE EDITORS
OF REVIEW OF OPHTHALMOLOGY SAVOR A SWEET MOMENT. They were named as
Finalists in four categories of this year¡¯s Jesse H. Neal National Business
Journalism Awards, presented by American Business Media. Pictured (front row,
l to r) are editor-in-chief Christopher Glenn, senior editor
Walter Bethke, senior editor Gillian McDermott, (back row, l to r)
associate editor Michael Beirne and art director Frank Sau.
- MEDENNIUM RECEIVES AUSTRALIAN APPROVAL OF SMART
PLUG. Medennium¡¯s SmartPlug, a one-size-fits-all punctum plug, received a
Certificate of Listing in the Australian Therapeutic Goods Administration
Register. This approval allows SmartPlug to be sold in Australia, and it follows
the 2001 approvals in Europe and Canada. SmartPlug is unique in that it is made
of a thermodynamic acrylic polymer. It is a thin rigid rod when removed from the
package, but seconds after insertion into the punctum it transforms into a soft
gel-like, long-term plug that conforms to the patient¡¯s punctum.
VISION RESEARCH LAUNCHES THERATEARS IN CANADA. Advanced Vision Research has
introduced preservative-free TheraTears Lubricant Eye Drops to eyecare
professionals and pharmacy retailers across Canada. TheraTears, which not only
wet but also rehydrate dry eyes, will be available in 24 single-use containers
(0.6ml each) for sale to pharmacies and eyecare specialists across Canada. Free
samples and patient brochures in both French and English are available by
- VITREOUS HEMORRHAGE DRUG MISSES PRIMARY GOAL IN
TRIAL. Drug developer ISTA Pharmaceuticals said Vitrase, its experimental
drug intended to treat severe vitreous hemorrhage, did not meet its primary goal
in late-stage clinical trials. ISTA said Vitrase did not show a statistically
significant improvement over placebo in achieving the primary target of the
trials. The primary endpoint was clearing the vitreous hemorrhage enough to
allow diagnosis and treatment of the underlying cause of the bleeding within
three months after taking Vitrase.
- NEI SAYS
AGE-RELATED THREATS TO SIGHT MAY NEARLY DOUBLE BY 2030. An estimated 3.5
million people are nearly or completely blind in the United States today. This
figure will double by 2030 if preventive measures in eye care are not taken,
according to a report from the National Eye Institute and Prevent Blindness
America. Nearly 2 million people will be completely blind by this time, and 3.2
million people will have extremely poor vision, according to David S. Friedman,
MD, MPH, principal investigator of the report.
BACALL SPEAKS OUT ABOUT AMD. Actress Lauren Bacall is the spokesperson for a
new campaign, "Raising America¡¯s Eye-Q," aimed at raising awareness about
macular degeneration. The campaign will encourage people to take a pledge for healthy
vision as a reminder to get annual eye exams. A Novartis Ophthalmics-sponsored
survey found that Americans over age 45 lack awareness about macular
degeneration and the importance of screening for it.
Send them to AllAboutVision.com, a website you can trust to
properly educate your patients on eye health and vision correction options. The
site contains more than 500 pages of information on contact lenses, eyeglasses, refractive surgery, eye problems and
diseases, and much